89bio, Inc.
NASDAQ:ETNB
Overview | Financials
Company Name | 89bio, Inc. |
Symbol | ETNB |
Currency | USD |
Price | 10.45 |
Market Cap | 1,106,759,500 |
Dividend Yield | 0% |
52-week-range | 6.88 - 16.63 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Rohan Palekar |
Website | https://www.89bio.com |
An error occurred while fetching data.
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD